Cough-generated aerosols of Pseudomonas aeruginosa and other Gram-negative bacteria from patients with cystic fibrosis
- PMID: 19574243
- PMCID: PMC2764123
- DOI: 10.1136/thx.2008.112466
Cough-generated aerosols of Pseudomonas aeruginosa and other Gram-negative bacteria from patients with cystic fibrosis
Abstract
Background: Pseudomonas aeruginosa is the most common bacterial pathogen in patients with cystic fibrosis (CF). Current infection control guidelines aim to prevent transmission via contact and respiratory droplet routes and do not consider the possibility of airborne transmission. It was hypothesised that subjects with CF produce viable respirable bacterial aerosols with coughing.
Methods: A cross-sectional study was undertaken of 15 children and 13 adults with CF, 26 chronically infected with P aeruginosa. A cough aerosol sampling system enabled fractioning of respiratory particles of different sizes and culture of viable Gram-negative non-fermentative bacteria. Cough aerosols were collected during 5 min of voluntary coughing and during a sputum induction procedure when tolerated. Standardised quantitative culture and genotyping techniques were used.
Results: P aeruginosa was isolated in cough aerosols of 25 subjects (89%), 22 of whom produced sputum samples. P aeruginosa from sputum and paired cough aerosols were indistinguishable by molecular typing. In four cases the same genotype was isolated from ambient room air. Approximately 70% of viable aerosols collected during voluntary coughing were of particles <or=3.3 microm aerodynamic diameter. P aeruginosa, Burkholderia cenocepacia, Stenotrophomonas maltophilia and Achromobacter xylosoxidans were cultivated from respiratory particles in this size range. Positive room air samples were associated with high total counts in cough aerosols (p = 0.003). The magnitude of cough aerosols was associated with higher forced expiratory volume in 1 s (r = 0.45, p = 0.02) and higher quantitative sputum culture results (r = 0.58, p = 0.008).
Conclusion: During coughing, patients with CF produce viable aerosols of P aeruginosa and other Gram-negative bacteria of respirable size range, suggesting the potential for airborne transmission.
Conflict of interest statement
None.
Figures



Comment in
-
Furthering our understanding of pathogen transmission in cystic fibrosis.Thorax. 2009 Nov;64(11):921-2. doi: 10.1136/thx.2009.119495. Thorax. 2009. PMID: 19864537 No abstract available.
Similar articles
-
Viability of Pseudomonas aeruginosa in cough aerosols generated by persons with cystic fibrosis.Thorax. 2014 Aug;69(8):740-5. doi: 10.1136/thoraxjnl-2014-205213. Epub 2014 Apr 17. Thorax. 2014. PMID: 24743559 Free PMC article.
-
Cystic fibrosis pathogens survive for extended periods within cough-generated droplet nuclei.Thorax. 2019 Jan;74(1):87-90. doi: 10.1136/thoraxjnl-2018-211567. Epub 2018 Apr 7. Thorax. 2019. PMID: 29627800
-
Face Masks and Cough Etiquette Reduce the Cough Aerosol Concentration of Pseudomonas aeruginosa in People with Cystic Fibrosis.Am J Respir Crit Care Med. 2018 Feb 1;197(3):348-355. doi: 10.1164/rccm.201707-1457OC. Am J Respir Crit Care Med. 2018. PMID: 28930641
-
Defining routes of airborne transmission of Pseudomonas aeruginosa in people with cystic fibrosis.Expert Rev Respir Med. 2010 Aug;4(4):519-29. doi: 10.1586/ers.10.42. Expert Rev Respir Med. 2010. PMID: 20658913 Review.
-
Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis.Am J Respir Med. 2003;2(4):321-32. doi: 10.1007/BF03256660. Am J Respir Med. 2003. PMID: 14719998 Review.
Cited by
-
HALTing Nontuberculous Mycobacteria in Cystic Fibrosis Centers: Is There Something in the Water?Am J Respir Crit Care Med. 2022 May 1;205(9):982-983. doi: 10.1164/rccm.202202-0337ED. Am J Respir Crit Care Med. 2022. PMID: 35275803 Free PMC article. No abstract available.
-
Documentary Research of Human Respiratory Droplet Characteristics.Procedia Eng. 2015;121:1365-1374. doi: 10.1016/j.proeng.2015.09.023. Epub 2015 Oct 7. Procedia Eng. 2015. PMID: 32288921 Free PMC article.
-
Microbiological diagnostic procedures for respiratory cystic fibrosis samples in Spain: towards standard of care practices.BMC Microbiol. 2014 Dec 24;14:335. doi: 10.1186/s12866-014-0335-y. BMC Microbiol. 2014. PMID: 25927861 Free PMC article.
-
Physiotherapy for cystic fibrosis in Australia and New Zealand: A clinical practice guideline.Respirology. 2016 May;21(4):656-67. doi: 10.1111/resp.12764. Epub 2016 Apr 18. Respirology. 2016. PMID: 27086904 Free PMC article.
-
Use of an innovative and non-invasive device for virologic sampling of cough aerosols in patients with community and hospital acquired pneumonia: a pilot study.J Breath Res. 2019 Mar 1;13(2):021001. doi: 10.1088/1752-7163/aaf010. J Breath Res. 2019. PMID: 30523983 Free PMC article.
References
-
- Cystic Fibrosis Foundation Cystic Fibrosis Foundation Patient Registry Annual Report 2000 Bethesda, MD: Cystic Fibrosis Foundation, 2001
-
- Rosenfeld M, Ramsey B, Gibson R. Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management. Curr Opin Pulm Med 2003;9:492–7 - PubMed
-
- Ramsey B. To cohort or not to cohort: how transmissible is Pseudomonas aeruginosa? Am J Respir Crit Care Med 2002;166:906–7 - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical